(23) evaluated the results of KRAS mutation in patients with advanced non-small cell lung cancer (NSCLC) with high expression of PD-L1 on treatment with first-line immune checkpoint inhibitors. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.